Patents by Inventor Kevin W. Moore

Kevin W. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN RECEPTOR PROTEINS; RELATED REAGENTS AND METHODS
    Publication number: 20080233111
    Abstract: Nucleic acids encoding mammalian, e.g., primate or rodent receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
    Type: Application
    Filed: March 4, 2008
    Publication date: September 25, 2008
    Applicant: Schering Corporation
    Inventors: Christi L. Parham, Kevin W. Moore, Nicholas J. Murgolo, J. Fernando Bazan
  • Mammalian receptor protein DCRS5;methods of treatment
    Patent number: 7422743
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: September 9, 2008
    Assignee: Schering Corporation
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
  • DCRS5 polypeptides
    Patent number: 7411041
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Grant
    Filed: September 18, 2003
    Date of Patent: August 12, 2008
    Assignee: Schering Corporation
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
  • USES OF MAMMALIAN CYTOKINE; RELATED REAGENTS
    Publication number: 20080145361
    Abstract: Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.
    Type: Application
    Filed: February 5, 2008
    Publication date: June 19, 2008
    Applicant: Schering Corporation
    Inventors: Edward P. Bowman, Shi-Juan Chen, Daniel J. Cua, Kevin W. Moore, Tatyana Churakova, Hong-Nhung Y. Nguyen, Jason R. Chan
  • DIRS1 antibodies
    Patent number: 7342103
    Abstract: The present invention provides nucleic acids encoding mammalian, e.g., primate or rodent receptors, purified receptor proteins and fragments thereof, and antibodies against these receptor proteins. Methods of using these compositions for both diagnostic and therapeutic utilities are also provided.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: March 11, 2008
    Assignee: Schering Corporation
    Inventors: Christi L. Parham, Kevin W. Moore, Nicholas J. Murgolo, J. Fernando Bazan
  • Mammalian receptor proteins; related reagents and methods
    Publication number: 20040258686
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: November 21, 2003
    Publication date: December 23, 2004
    Applicant: Schering Corporation, a New Jersey corporation
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
  • Uses of mammalian cytokine; related reagents
    Publication number: 20040213761
    Abstract: Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.
    Type: Application
    Filed: December 18, 2003
    Publication date: October 28, 2004
    Inventors: Edward P. Bowman, Shi-Juan Chen, Daniel J. Cua, Kevin W. Moore, Tatyana Churakova, Hong-Nhung Y. Nguyen, Jason R. Chan
  • IL-23 receptor binding compositions
    Patent number: 6756481
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: June 29, 2004
    Assignee: Schering Corporation
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
  • Human receptor proteins; related reagents and methods
    Publication number: 20030224427
    Abstract: Nucleic acids encoding mammalian, e.g., primate or rodent receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
    Type: Application
    Filed: April 10, 2003
    Publication date: December 4, 2003
    Applicant: Schering Corporation, a New Jersey corporation
    Inventors: Christi L. Parham, Kevin W. Moore, Nicholas J. Murgolo, J. Fernando Bazan
  • Polynucleotides encoding DIRS1
    Patent number: 6586228
    Abstract: Nucleic acids encoding mammalian, e.g., primate or rodent receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: July 1, 2003
    Assignee: Schering Corporation
    Inventors: Christi L. Parham, Kevin W. Moore, Nicholas J. Murgolo
  • Mammalian receptor proteins; related reagents and methods
    Publication number: 20030017617
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: May 10, 2001
    Publication date: January 23, 2003
    Applicant: Schering Corporation, a New Jersey Corporation
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
  • Mammalian receptors for interleukin-10
    Patent number: 6423500
    Abstract: Receptor components for IL-10 are isolated and characterized. The amino acid sequence and nucleic acid encoding various species variants of the receptors are disclosed. Uses of the purified receptor gene and polypeptide are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: July 23, 2002
    Assignee: Schering Corporation
    Inventors: Kevin W. Moore, Ying Liu, Alice Suk-Yue Ho, Di-Hwei Hsu, Bazan Fernando J., Jimmy C. Tan, Chuan-Chu Chou
  • Treatment of neoplastic disease with interleukin-10
    Patent number: 6319493
    Abstract: A method is provided for treating tumors, e.g., lymphocytic leukemias, which comprises administering to a mammal an effective amount of interleukin-10.
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: November 20, 2001
    Assignee: Schering Corporation
    Inventors: Paulo J. Vieira, Kevin W. Moore, Rene de Waal Malefyt, Jan E. de Vries, Anne-Catherine Fluckiger, Jacques Banchereau
  • Methods of treatment using cytokine synthesis inhibitory factor
    Patent number: 6312680
    Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs now known as Interleukin-10 (IL-10)), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-&ggr;.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 6, 2001
    Inventors: Timothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira
  • Human FC&ggr; receptor III
    Patent number: 6294347
    Abstract: Soluble and membrane-bound forms of human Fc&ggr;RIII are provided, together with nucleic acids capable of encoding the same. Soluble Fc&ggr;RIIIs are useful in ameliorating the serum platelet deficiency associated with immune thrombocytopenic prupura. Cells expressing membrane-bound Fc&ggr;RIIIs are useful components in assays for serum immune complexes.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: September 25, 2001
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Gary A. Peltz, Kevin W. Moore
  • Binding compositions specific for interleukin-10
    Patent number: 6239260
    Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs) or interleukin 10 (IL-10), as well as antibodies which specifically bind IL-10, are provided. These proteins, and antibodies, may be used to treat various disease states associated with cytokine imbalances.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 29, 2001
    Assignee: Schering Corporation
    Inventors: Timothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira
  • Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
    Patent number: 6217857
    Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIF's, now known as Interleukin-10 (IL-10)), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-&ggr;.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 17, 2001
    Assignee: Schering Corporation
    Inventors: Timothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira
  • Methods of treatment using antagonists of cytokine synthesis inhibitory factor
    Patent number: 6207154
    Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs, now known as Interleukin-10 (IL-10)), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-&ggr;.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 27, 2001
    Assignee: Schering Corporation
    Inventors: Timothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira
  • Treatment of neoplastic disease with interleukin-10
    Patent number: 6106823
    Abstract: A method is provided for treating tumors, e.g., lymphocytic leukemias, which comprises administering to a mammal an effective amount of interleukin-10.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: August 22, 2000
    Assignee: Schering Corporation
    Inventors: Paulo J. Vieira, Kevin W. Moore, Rene de Waal Malefyt, Jan E. de Vries, Anne-Catherine Fluckiger, Jacques Banchereau
  • Nucleic acids encoding cytokine synthesis inhibitory factor (Interleukin-10)
    Patent number: 6018036
    Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs, now known as Interleukin-10 (IL-10)), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-.gamma..
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 25, 2000
    Assignee: Schering Corporation
    Inventors: Timothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira